Hit enter to search or ESC to close
Company
Science
Pipeline
Newsroom
Investors
Careers
Contact
Overview
News Releases
Events
Stock Information
Quote
Interactive Chart
Corporate Governance
Documents & Charters
Board Committees
Financial Information
Snapshot
SEC Filings
Analyst Coverage
Key Ratios
Investor Resources
Contact IR
FAQs
Investor Alerts
RSS
Investors Menu
Overview
News Releases
Events
Stock Information
Quote
Interactive Chart
Corporate Governance
Documents & Charters
Board Committees
Financial Information
Snapshot
SEC Filings
Analyst Coverage
Key Ratios
Investor Resources
Contact IR
FAQs
Investor Alerts
RSS
News Releases
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Investor Alerts
Year
All Years
2023
2022
2021
2020
2019
2018
2017
2016
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Jun 28, 2022
IDEAYA Announces Development Candidate Nomination of a Potential First-in-Class Pol Theta Helicase Inhibitor in Collaboration with GSK
Jun 8, 2022
IDEAYA Biosciences to Present at the 2022 Jefferies Global Healthcare Conference
May 10, 2022
IDEAYA Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
May 3, 2022
IDEAYA Biosciences to Participate in Investor Conferences in May 2022
May 2, 2022
IDEAYA Biosciences Receives Orphan Drug Designation for Darovasertib, a PKC Inhibitor, for the Treatment of Uveal Melanoma
Apr 6, 2022
IDEAYA Biosciences Appoints Catherine Mackey, Ph.D., to its Board of Directors
Mar 15, 2022
IDEAYA Biosciences, Inc. Reports 2021 Financial Results and Provides Business Update
Mar 15, 2022
IDEAYA Biosciences Reports IDE397 Interim Phase 1 Clinical Data
Mar 14, 2022
IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreements for Evaluation of Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma and Additional cMET-Driven Tumors
Mar 8, 2022
IDEAYA Biosciences Announces Investor Webcast to Report Interim IDE397 Phase 1 Clinical Data and Corporate Update
Show
5
10
25
50
100
per page
«
1
2
3
4
5
6
7
8
9
…
15
»
Company
Science
Pipeline
Newsroom
Investors
Careers
Contact